Anorectic drugs: an experimental and clinical perspective-A Review

被引:0
作者
Priya, Sindhu K.
Thangavelu, Lakshmi [1 ]
Geetha, R., V
Rajeshkumar, S.
Raghunandhakumar, S.
Roy, Anitha
机构
[1] Saveetha Univ, Saveetha Dent Coll, Dept Pharmacol, SIMATS, Chennai, Tamil Nadu, India
来源
JOURNAL OF COMPLEMENTARY MEDICINE RESEARCH | 2020年 / 11卷 / 05期
关键词
diabetes mellitus; empagliflozin; metformin; metabolic syndrome; drugs; ROOT-CANAL SEALERS; FENPROPOREX; AMPHETAMINE; NANOPARTICLES; METABOLISM; PRESCRIPTION; ANTIOXIDANT; METFORMIN; AGENT;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Obesity is a highly prevalent disease that continuously rises and is a major problem to solve. It is associated with mortality, morbidity, diet, and treatment costs. The need for new drugs that are effective and long lasting is the primary concern for all health care professionals. There have been lots of researches recently targeting diabetes, one showed the blockage of sodium-glucose co transporter 2 (SGLT2). It had a high glycemic index and weight-lowering potential. Dual drug therapy was suggested to be highly significant in treating diabetes -2. Fixed dose combination therapy shows an attractive option, since it reduces pill burden and improves adherence. Drugs used was metformin and empagliflozin. Another research was done in order to acquire a balanced homeostatic energy. Disregulating one of its components can lead to obesity. Altering homeostatic signals can alter the vulnerability for drug abuse. It focuses on single protein target, lorcaslin and orlistat are the main anti-obesity drugs. Metabolic syndrome is cluster of associated metabolic traits that increases development of CVD and dsiabetes. Seratonergic drugs and inhibitors of pancreatic lipases are used as long-term of obesity. New classes of drugs like glucagon-like peptide 1receptor agonists act on the hunger and satiety centres and favourably impact the associated traits.
引用
收藏
页码:106 / 112
页数:7
相关论文
共 51 条
[1]   7. Approaches to Glycemic Treatment [J].
不详 .
DIABETES CARE, 2016, 39 :S52-S59
[2]   Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease [J].
Ashok, Ben Sundra ;
Ajith, Thekkuttuparambil Ananthanarayanan ;
Sivanesan, Senthilkumar .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2017, 44 (03) :327-334
[3]  
Attie Jr M, 1972, FOLHA MED, V64, P705
[4]   INFLUENCE OF REPLACEMENT OF N-ETHYL GROUP BY CYANOETHYL GROUP ON ABSORPTION, DISTRIBUTION AND METABOLISM OF (+/-)-ETHYLAMPHETAMINE IN MAN [J].
BECKETT, AH ;
SALMON, JA ;
SHENOY, EVB .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1972, 24 (03) :194-&
[5]  
Chiorboli E, 1975, FOLHA MED, V71, P425
[6]   Detection of amphetamine following administration of fenproporex [J].
Cody, JT ;
Valtier, S .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1996, 20 (06) :425-431
[7]   Amphetamine and fenproporex levels following multidose administration of fenproporex [J].
Cody, JT ;
Valtier, S .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1999, 23 (03) :187-194
[8]   The Return of Rainbow Diet Pills [J].
Cohen, Pieter A. ;
Goday, Alberto ;
Swann, John P. .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2012, 102 (09) :1676-1686
[9]   Imported Fenproporex-based Diet Pills from Brazil: A Report of Two Cases [J].
Cohen, Pieter A. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 (03) :430-433
[10]   Anorectics on trial: A half century of federal regulation of prescription appetite suppressants [J].
Colman, E .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (05) :380-385